Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

PHASE4CompletedINTERVENTIONAL
Enrollment

388

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

July 31, 2004

Conditions
Osteoarthritis, Knee
Interventions
DRUG

Celecoxib

200 mg oral capsule once daily with morning meal for 6 weeks

OTHER

Placebo

Matched oral placebo for 6 weeks

Trial Locations (33)

11203

Pfizer Investigational Site, Brooklyn

13901

Pfizer Investigational Site, Binghamton

15904

Pfizer Investigational Site, Johnstown

20006

Pfizer Investigational Site, Washington D.C.

20902

Pfizer Investigational Site, Wheaton

22203

Pfizer Investigational Site, Arlington

23502

Pfizer Investigational Site, Norfolk

27103

Pfizer Investigational Site, Winston-Salem

27609

Pfizer Investigational Site, Cary

29407

Pfizer Investigational Site, Charleston

32779

Pfizer Investigational Site, Longwood

33186

Pfizer Investigational Site, Miami

33540

Pfizer Investigational Site, Zephyrhills

35235

Pfizer Investigational Site, Birmingham

37825

Pfizer Investigational Site, New Tazewell

58506

Pfizer Investigational Site, Bismarck

59715

Pfizer Investigational Site, Bozeman

60053

Pfizer Investigational Site, Morton Grove

65807

Pfizer Investigational Site, Springfield

67206

Pfizer Investigational Site, Wichita

67214

Pfizer Investigational Site, Wichita

78229

Pfizer Investigational Site, San Antonio

80204

Pfizer Investigational Site, Denver

83704

Pfizer Investigational Site, Boise

83706

Pfizer Investigational Site, Boise

90620

Pfizer Investigational Site, Buena Park

97239

Pfizer Investigational Site, Portland

97401

Pfizer Investigational Site, Eugene

98166

Pfizer Investigational Site, Seattle

08611

Pfizer Investigational Site, Trenton

10022-1009

Pfizer Investigational Site, New York

16635-0909

Pfizer Investigational Site, Duncansville

02886

Pfizer Investigational Site, Warwick

All Listed Sponsors
lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00638807 - Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen | Biotech Hunter | Biotech Hunter